Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study

Chih-Ching Yeh, Chih‐Ching Yeh, Yeh CC, Fu-Hsiung Su, Fu‐Hsiung Su, Tzeng CR, Chii-Ruey Tzeng, Chii‐Ruey Tzeng, Chih-Hsin Muo, Muo CH, Wen‐Chang Wang
PloS one · 2018 · vol. 13(3) , pp. e0194011 · doi:10.1371/journal.pone.0194011 · PMID:29522577 · PMC5844548 · W2790073489
article OA: gold CC0 ⤵ 35 in-corpus citations
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Women with adenomyosis had increased risks for endometrial and thyroid cancers, while women with endometriosis showed higher risks for endometrial and ovarian cancers.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

This nationwide population-based historical cohort study used Taiwan’s National Health Insurance Research Database to compare cancer-free survival between 12,447 women with adenomyosis (excluding those with endometriosis) and 124,470 matched adenomyosis-free women, and then evaluated whether time-to-cancer onset tracked with time-to-adenomyosis onset. Using ICD-9-CM diagnoses and a two-stage Cox model with adjustments for measured demographics/comorbidities and birth year, the study found higher risks of endometrial cancer (HR 2.19) and thyroid cancer (HR 1.70) in the adenomyosis cohort, with no significant differences in cancer-free survival between early- and late-diagnosed adenomyosis groups for these cancers. For comparison, women with endometriosis (excluding adenomyosis) had higher risks of endometrial (HR 1.89) and ovarian cancer (HR 2.01) versus endometriosis-free controls, but the paper does not report any causal mechanism. This paper is centrally about endometriosis and adenomyosis overlap — it quantifies adenomyosis-associated increased risks of endometrial cancer and directly compares them with endometriosis-associated cancer risks.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: Both adenomyosis and endometriosis are characterized by the presence of ectopic endometrial glands and stroma and have been suggested to share some characteristics with malignant tumors. Although accumulating evidence indicates that endometriosis is associated with some cancer types, the cancer risks in patients with adenomyosis have been rarely examined. In this study, we investigated the relationship between adenomyosis and risks of common cancers. METHODS: This study included a cohort of 12,447 women with adenomyosis but not endometriosis, born in 1951-1984, and a cohort of 124,470 adenomyosis-free women matched by birth year. Their medical records (collected between 1996 and 2011) were obtained from the National Health Insurance Research Database of Taiwan. We first compared the distribution of cancer-free survival (CFS) between cohorts with and without adenomyosis. Subsequently, within the adenomyosis cohort, we examined whether time-to-onset of the identified cancer type was correlated with time-to-onset of adenomyosis. The Cox proportional hazards model was used to compare the distribution of CFS between the adenomyosis and adenomyosis-free cohorts and between the early- and late-diagnosed adenomyosis groups. For comparison, we further evaluated the cancer risks for a cohort of 10,962 women with endometriosis but not adenomyosis and a birth-year matched cohort of 109,620 endometriosis-free women. RESULTS: Compared with adenomyosis-free women, patients with adenomyosis had higher risks of endometrial and thyroid cancers, with estimated hazard ratios (HRs) (95% confidence interval) of 2.19 (1.51-3.16) and 1.70 (1.29-2.24), respectively. For both cancers, distributions of CFS were not significantly different between the early- and late-diagnosed adenomyosis groups. Furthermore, compared with endometriosis-free women, patients with endometriosis had higher risks of endometrial and ovarian cancers, with HRs of 1.89 (1.07-3.35) and 2.01 (1.27-3.16), respectively. CONCLUSIONS: Women with adenomyosis are at higher risks of endometrial and thyroid cancers, while women with endometriosis are at higher risks of endometrial and ovarian cancers.
Full text 20,706 characters · extracted from pmc-nxml · 5 sections · click to expand

Intro

Adenomyosis and endometriosis are two common gynecologic diseases, and both are characterized by the presence of ectopic endometrial glands and stroma [ 1 , 2 ]. These diseases are commonly diagnosed in reproductive-age women, and they can result in pelvic pain, dysmenorrhea, and infertility [ 3 ]. Although adenomyosis and endometriosis are generally considered benign conditions, they have been suggested to share some characteristics with malignant tumors, such as angiogenesis, abnormal tissue growth, and invasion [ 4 , 5 ]. In recent years, an increasing number of studies have investigated the association of endometriosis with several cancer types [ 5 ], particularly ovarian cancer [ 6 ]. However, few studies have examined the association of adenomyosis with cancer risk [ 7 ], except for risk of endometrial cancer [ 8 – 12 ]. In this study, based on a large nationwide database collected in Taiwan, we investigated the relationship between adenomyosis and the risks of different cancer types by using a two-stage approach. First, we examined whether the risks of some cancer types in patients with adenomyosis are different from those in the general population. Then, for each cancer type associated with adenomyosis, we examined whether the time of cancer onset is correlated with the time of adenomyosis onset. To investigate whether cancer types associated with adenomyosis is identical to those associated with endometriosis, we also examined the association between endometriosis and different cancer types in our first-stage analysis.

Results

As shown in S1 Table , the LHID2000 contained data of 280,419 women born between 1951 and 1984. Of them, 249,541 (89%) had been unaffected by adenomyosis or endometriosis. Among the 30,878 (11%) women affected by adenomyosis or endometriosis, 12,447 (4.4%) women were affected by adenomyosis only, 10,962 (3.9%) women were affected by endometriosis only, and the remaining 7,469 (2.7%) women were simultaneously affected by adenomyosis and endometriosis. When stratifying the study population by birth year, the highest proportion of women affected by adenomyosis or endometriosis (15.5%) was found in the stratum of women born in 1962, the highest proportion of women affected by adenomyosis only (8.2%) was found in the stratum of women born in 1960, and the highest proportion of women affected by endometriosis only (5.2%) was found in the stratum of women born in 1977. The results of comparisons of demographic characteristic and comorbidities between adenomyosis and adenomyosis-free cohorts and between endometriosis and endometriosis-free cohorts are summarized in Table 2 and S3 Table , respectively. As shown in these tables, all demographic characteristics and comorbidities examined were significantly different not only between the adenomyosis and adenomyosis-free cohorts but also between the endometriosis and endometriosis-free cohorts. Therefore, these variables were adjusted for in the first-stage association analysis. The distribution of cancer types in the adenomyosis cohort is summarized in Table 1 . The patient numbers for cancers of the head and neck, colon and rectum, liver, lung, breast, endometrium, cervix, ovary, thyroid, and lymphatic and hematopoietic tissue were more than or equal to 10. Among these cancers, adenomyosis and cancer were detected within an interval of 6 months in high proportions of the patients with cancers of the endometrium (64.47%), cervix (84.21%), and ovary (52.94%). Similarly, distribution of cancer types in the endometriosis cohort is summarized in S2 Table . The patient numbers for cancers of the head and neck, stomach, colon and rectum, breast, endometrium, cervix, ovary, thyroid, and lymphatic and hematopoietic tissue were more than or equal to 10. Among these cancers, endometriosis and cancer were detected within an interval of 6 months in high proportions of the patients with cancers of the endometrium (52.38%), cervix (63.16%), and ovary (55.56%). For individual cancer types, the results of comparisons of the distributions of CFS between the adenomyosis and adenomyosis-free cohorts are summarized in Table 3 . As shown in Table 3 , compared with the matched adenomyosis-free cohort, the adenomyosis cohort had significantly higher risks of endometrial cancer and thyroid cancer, with adjusted HRs of 2.19 (95%CI: 1.51–3.16) and 1.70 (95%CI: 1.29–2.24), respectively, as shown in Fig 1 . (A) CFS curves for endometrial cancer. (B) CFS curves for thyroid cancer.), for both endometrial and thyroid cancers, the CFS curve of the adenomyosis cohort significantly deviated from that of the adenomyosis-free cohort (both p < 0.001). a per 10000 person-year. b Adjusted for birth year and significant variables in Table 2 . c p value < 0.001. The results of comparisons of the distributions of CFS between the endometriosis and endometriosis-free cohorts are summarized in S4 Table . Compared with the matched endometriosis-free cohort, the endometriosis cohort had significantly higher risks of endometrial cancer and ovarian cancer, and the adjusted HRs were 1.89 (95%CI: 1.07–3.35) and 2.01 (95%CI: 1.27–3.16), respectively. For endometrial and ovarian cancers, the CFS curves in the endometriosis and endometriosis-free cohorts are presented in S1 Fig and significant difference in CFS curves between endometriosis and endometriosis-free cohorts was observed for both cancer types ( p = 0.008 and 0.003, respectively). For comparison, the ovarian CFS curves in adenomyosis and adenomyosis-free cohorts and the thyroid CFS curves in endometriosis and endometriosis-free cohorts were also estimated and shown in S2 and S3 Figs, respectively, and no significant difference was observed in both scenarios ( p = 0.422 and 0.438, respectively). For endometrial cancer and thyroid cancer, the results of comparisons of the distributions of CFS between women with early-diagnosed adenomyosis and women with late-diagnosed adenomyosis are summarized in Table 4 . For both cancer types, no significant difference was observed. Specifically, in women with late-diagnosed adenomyosis, compared with women with early-diagnosed adenomyosis, the adjusted HRs for endometrial cancer and thyroid cancer were 0.79 (95%CI: 0.37–1.69) and 1.10 (95%CI: 0.66–1.83), respectively. a per 10000 person-year. b Adjusted for birth year. c p value > 0.05.

Conclusions

According to the observations in our study, the spectrum of cancer types associated with adenomyosis did not seem to be identical to that of cancer types associated with endometriosis. This study revealed a significant association of adenomyosis with endometrial cancer and thyroid cancer. However, we could not provide conclusive evidence regarding whether the time-to-onset of adenomyosis is correlated with that of endometrial cancer and thyroid cancer. Further efforts are needed to reveal the exact mechanisms underlying the association observed in this study.

Materials|Methods

This study was approved by the Institutional Review Board of China Medical University and the Research Ethics Committee of China Medical University Hospital (IRB permit number: CMU-REC-101-012). We used data from the Longitudinal Health Insurance Database 2000 (LHID2000), which is a subset of the National Health Insurance Research Database (NHIRD) in Taiwan. The NHIRD consists of the data of insurants enrolled in the National Health Insurance program, which was launched in 1995 and covers more than 99% of Taiwan’s population [ 13 , 14 ]. The LHID2000 consists of the medical records (collected between 1996 and 2011) of one million beneficiaries randomly sampled from the NHIRD ( http://nhird.nhri.org.tw/en/Data_Subsets.html#S3 ). A total of 486,077 women were contained in the LHID2000. As shown in S1 Table , we stratified these women by their birth year, and calculated the proportions of women having at least one diagnostic record of adenomyosis (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 617.0)[ 3 ] or endometriosis (ICD-9-CM codes 617.1–617.9)[ 3 ] in individual strata. According to S1 Table , we selected women born between 1951 and 1984 as the study population because more than 5% of women had a diagnosis of adenomyosis or endometriosis in each of these strata. The study population was divided into four cohorts: (1) adenomyosis cohort, (2) endometriosis cohort, (3) both adenomyosis and endometriosis cohort, and (4) adenomyosis-and-endometriosis-free cohort. The distribution of cancer types in the adenomyosis cohort was summarized in Table 1 . In this study, we only analyzed cancer types for which the patient numbers were more than or equal to 10. For each cancer type, the patients were further classified into four subsets, according to the order of diagnoses of cancer and adenomyosis (adenomyosis diagnosed before cancer or cancer diagnosed before adenomyosis) and the interval between these two events (within or more than 6 months). For a disease, the time of diagnosis was defined as the time of its first diagnostic record in the LHID2000. Similarly, the distribution of cancer types in the endometriosis cohort was summarized in S2 Table . The two-stage approach used in this study was designed as follows. In the first stage, for each cancer type, we compared the distribution of cancer-free survival (CFS) between the adenomyosis cohort and a matched adenomyosis-free cohort, to look for cancer types for which the cancer risk in patients with adenomyosis is different from that in the general population. The first-stage analysis was similar to previous studies [ 7 , 15 ], except that we did not exclude patients who received the cancer diagnosis before the adenomyosis diagnosis. In the second stage, for each cancer type identified in the first stage, we compared the distribution of CFS between women with early-diagnosed adenomyosis and women with late-diagnosed adenomyosis, to investigate whether time of cancer onset is correlated with time of adenomyosis onset. In the first-stage analysis, the patients who received the cancer diagnosis within 6 months after the adenomyosis diagnosis were excluded from the adenomyosis cohort, because their time of cancer diagnosis were likely to be advanced by the examination and treatment of adenomyosis, and the inclusion of these data may result in artificial difference in the distribution of CFS between adenomyosis and adenomyosis-free cohorts. Subsequently, to generate a matched adenomyosis-free cohort used in the first-stage analysis, for each patient in the adenomyosis only cohort, 10 women matched by birth year were randomly sampled from the adenomyosis-and-endometriosis-free cohort. In the second-stage analysis, the patients who received the cancer diagnosis within 6 months before the adenomyosis diagnosis were further excluded from the adenomyosis cohort. For the patients whose adenomyosis was detected within a short time after the cancer diagnosis, the time of adenomyosis diagnosis was likely to be advanced by the examination and treatment of cancer. Subsequently, the remaining patients were divided into 34 strata by their birth year, and the medians of the age of adenomyosis onset in individual strata were calculated. In each stratum, the patients whose age-at-onset was less than the median were defined to be early-diagnosed. All early-diagnosed patients formed the early-diagnosed adenomyosis group; the remaining patients formed the late-diagnosed adenomyosis group. We would like to note that the constructed groups necessarily have identical distributions of birth year and different distributions of CFS between the early- and late-diagnosed adenomyosis groups could be observed only if the time of cancer onset is correlated with the time of adenomyosis onset. The Pearson chi-squared test was used to compare demographic characteristics and comorbidities between adenomyosis and adenomyosis-free cohorts. The demographic characteristics examined were geographic region, occupation, urbanization level, and monthly income; the comorbidities examined comprised chronic obstructive pulmonary disease, hypertension, hyperlipidemia, diabetes, coronary artery disease, chronic renal disease, and pelvic inflammatory disease. In the first-stage analysis, for each cancer type, we compared the distribution of CFS in the adenomyosis cohort with that in the matched adenomyosis-free cohort by using the Cox proportional hazards model. The hazard ratio (HR) and its 95% confidence interval (CI) were estimated and adjusted for the demographic characteristics and comorbidities that were significantly different between the adenomyosis and adenomyosis-free cohorts as well as adjusted for birth year. Furthermore, the CFS curves were estimated by Kaplan-Meier approach and the difference in CFS curves between adenomyosis and adenomyosis-free cohorts was examined by the log-rank test. In the second-stage analysis, for each cancer type identified in the first-stage analysis, we also compared the distribution of CFS in the late-diagnosed adenomyosis group with that in the early-diagnosed adenomyosis group by using the Cox proportional hazards model. The HR and its 95% CI were estimated and adjusted for birth year. All statistical analyses were performed using SAS statistical software (version 9.4 for Windows; SAS Institute, Inc., Cary, NC, USA), and the significance level was set at 0.05. For comparison, the analytic procedures for first-stage analysis were also applied to the endometriosis cohort.

Supplementary Material

(XLSX) Click here for additional data file. (XLSX) Click here for additional data file. (XLSX) Click here for additional data file. (XLSX) Click here for additional data file. (A) CFS curves for endometrial cancer. (B) CFS curves for ovarian cancer. (TIF) Click here for additional data file. (TIF) Click here for additional data file. (TIF) Click here for additional data file.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisadenomyosis

MeSH descriptors

Adenomyosis Endometrial Neoplasms Thyroid Neoplasms Adenomyosis Adult Aged Age Distribution Cohort Studies Comorbidity Disease Susceptibility Endometrial Neoplasms Endometriosis Endometriosis Female Historically Controlled Study Humans Middle Aged Neoplasms Neoplasms Ovarian Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (39)

Cited by (36)

Source provenance

europepmc
last seen: 2026-10-07T06:10:45.703000+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:55.107525+00:00
License: CC0 · commercial use OK